2,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbaldehyde | 256529-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbaldehyde
• 英文别名: 2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde；2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]pyrrole-3-carbaldehyde
• CAS: 256529-25-6
• 化学式: C₁₄H₁₂F₃NO
• mdl: MFCD00115175
• 分子量: 267.251
• InChiKey: FNMOTVDVAVQQDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  343.0±42.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-methyl-3-oxo-1,2-dihydropyrrole-4-carboxylate 、 2,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbaldehyde 在 potassium hydrogensulfate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以85%的产率得到ethyl (5E)-5-[[2,5-dimethyl-1-[4-(trifluoromethyl)phenyl]pyrrol-3-yl]methylidene]-2-methyl-4-oxo-1H-pyrrole-3-carboxylate
  参考文献：
  名称：

  Discovery and Structure–Activity Relationships of Pyrrolone Antimalarials

  摘要：

  In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 similar to 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.

  DOI：

  10.1021/jm400009c
• 作为产物：
  描述：

  2,5-己二酮 在 对甲苯磺酸 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 17.5h， 生成 2,5-dimethyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbaldehyde
  参考文献：
  名称：

  具有激动剂/拮抗剂转换的新 FXR 配体化学型

  摘要：

  胆汁酸敏感转录因子法尼醇 X 受体 (FXR) 的治疗性调节是对抗肝脏和代谢疾病的一种有吸引力的策略。尽管有几种高效的 FXR 激动剂，但 FXR 调节剂的结构多样性是有限的，并且需要新的配体支架。在这里，我们报告了一种新的 FXR 调节剂化学型的结构-活性关系，其活性可以通过两个小的结构修饰在激动和拮抗之间进行调节。从弱 FXR/PPAR 激动剂开始，我们开发了具有纳摩尔到低微摩尔效力和结合亲和力的选择性 FXR 激活剂和拮抗剂。新的 FXR 配体化学型在天然细胞环境中调节 FXR 活性，具有良好的代谢稳定性，并且缺乏细胞毒性。

  DOI：

  10.1021/acsmedchemlett.0c00647

文献信息

• [EN] ANDROGEN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DES ANDROGÈNES
  申请人：ALPINE ANDROSCIENCES INC

  公开号：WO2019152731A1

  公开（公告）日：2019-08-08

  Compounds that inhibit the androgen receptor, pharmaceutical compositions comprising one or more of the compounds, as well as methods of treating cancer using such compounds are described.

  描述了抑制雄激素受体的化合物、包含一种或多种这些化合物的药物组合物，以及使用这些化合物治疗癌症的方法。
• Synthesis, Structure and In Vitro Anti-Trypanosomal Activity of Non-Toxic Arylpyrrole-Based Chalcone Derivatives
  作者：Ayanda I. Zulu、Ogunyemi O. Oderinlo、Cuan Kruger、Michelle Isaacs、Heinrich C. Hoppe、Vincent J. Smith、Clinton G. L. Veale、Setshaba D. Khanye

  DOI：10.3390/molecules25071668

  日期：——

  With an intention of identifying chalcone derivatives exhibiting anti-protozoal activity, a cohort of relatively unexplored arylpyrrole-based chalcone derivatives were synthesized in moderate to good yields. The resultant compounds were evaluated in vitro for their potential activity against a cultured Trypanosoma brucei brucei 427 strain. Several compounds displayed mostly modest in vitro anti-trypanosomal activity with compounds 10e and 10h emerging as active candidates with IC50 values of 4.09 and 5.11 µM, respectively. More importantly, a concomitant assessment of their activity against a human cervix adenocarcinoma (HeLa) cell line revealed that these compounds are non-toxic.

  为了确定具有抗原虫活性的蒲公英素衍生物，合成了一系列相对未被探索的基于芳基吡咯烯的蒲公英素衍生物，产率在中等到良好之间。所得化合物在体外评估其对培养的布鲁氏锥虫427株的潜在活性。几种化合物显示出主要是适度的体外抗锥虫活性，其中化合物10e和10h 显示出活性，IC50值分别为4.09和5.11微摩尔。更重要的是，对它们在人宫颈腺癌（HeLa）细胞系中的活性进行同时评估表明这些化合物无毒。
• Discovery and optimisation studies of antimalarial phenotypic hits
  作者：Alka Mital、Dinakaran Murugesan、Marcel Kaiser、Clive Yeates、Ian H. Gilbert

  DOI：10.1016/j.ejmech.2015.08.044

  日期：2015.10

  There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09-29 mu M, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds. (C) 2015 The Authors. Published by Elsevier Masson SAS.
• [EN] NOVEL COMPOUND AND PHARMACEUTICAL APPLICATION OF SAME<br/>[FR] NOUVEAU COMPOSÉ ET SON APPLICATION PHARMACEUTIQUE
  申请人：SANWA KAGAKU KENKYUSHO CO

  公开号：WO2009148004A1

  公开（公告）日：2009-12-10

  【課題】 　本発明は、医薬品として十分に満足できる、ＧＩＰの機能阻害、特にＧＩＰの受容体結合阻害に基づく、肥満、インスリン抵抗性、又は肝臓への脂質蓄積の予防又は改善剤を提供することを課題とする。 【解決手段】 　下記一般式（I）で表される化合物又はその医薬的に許容される塩である化合物、及び当該化合物を有効成分とする、ＧＩＰの受容体結合阻害剤、肥満等の予防又は改善剤が提供される。〔式中、例えば、WはCR1（R1はハロゲン原子又はシアノ基）等を表し、Zは、下記一般式（V1）、下記一般式（V2）、又は下記一般式（Y1）で表される基を意味する。〕（式中、例えば、Aは置換されていてもよいアリール基等、R2は置換されていてもよいアリール基等、R3は置換されていてもよいフェニルスルホニル基等、R4及びR5は水素又は置換されていてもよい炭素数１～３のアルキル基等を表す）
• Discovery and Structure–Activity Relationships of Pyrrolone Antimalarials
  作者：Dinakaran Murugesan、Alka Mital、Marcel Kaiser、David M. Shackleford、Julia Morizzi、Kasiram Katneni、Michael Campbell、Alan Hudson、Susan A. Charman、Clive Yeates、Ian H. Gilbert

  DOI：10.1021/jm400009c

  日期：2013.4.11

  In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 similar to 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.